NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $3,072,000 | -82.1% | 219,281 | -63.0% | 0.05% | -79.7% |
Q4 2021 | $17,166,000 | +317.0% | 592,941 | +331.5% | 0.25% | +267.2% |
Q3 2021 | $4,117,000 | -22.3% | 137,401 | -14.8% | 0.07% | -52.5% |
Q4 2020 | $5,301,000 | +5.4% | 161,211 | +11.9% | 0.14% | -14.5% |
Q3 2020 | $5,030,000 | – | 144,087 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |